NCT00132756终止1 期
Liposomal Doxorubicin and Estramustine Phosphate: A Phase II Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer
Morton Plant Mease Health Care2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2003年12月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Reduce the measurable disease and PSA level by at least 50%
研究概览
简要总结
The purpose of this research study is to test the safety, tolerability, and effectiveness of the drug combination of Doxil (doxorubicin) and estramustine when used to treat prostate cancer that is resistant to hormones and to a chemotherapy type called taxanes.
The primary hypothesis is to reduce the measurable disease or prostate-specific antigen (PSA) level by at least 50% from baseline.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically confirmed advanced, prostate cancer
- •Patients must have evaluable disease that may be evaluated by PSA or measurement.
- •Patients must be hormone refractory as defined in this protocol.
- •Patients must be taxane refractory as defined in this protocol.
- •Patients have had no prior chemotherapy other than a taxane or estramustine phosphate.
- •Patients may have had prior radiation therapy (RT) if it has been >/= 4 weeks since completion.
- •Patients on bisphosphonates may be included.
- •Patients must be at least 18 years of age or older.
- •Patients must have the ability to speak and understand English.
- •Patients must have an ECOG performance status of 2 or less.
- •Patients must have adequate bone marrow function: platelets > 100,000 cells/mm3; hemoglobin > 9.0 g/dL; and absolute neutrophil count (ANC) > 1,000 cells/mm
- •Patients must have adequate renal function: creatinine < 2.5 mg/dL.
- •Patients must have adequate liver function.
- •Ejection fraction of > 50% within 42 days of first dose of study drug.
- •Ability to complete the McGill-Melzack Pain Intensity Scale.
排除标准
- •Patients with unstable medical conditions such as liver, renal dysfunctions, blood clots or heart disease.
- •History of hypersensitivity to doxorubicin.
- •History of class II cardiac disease or evidence of congestive heart failure.
- •RT within the past 4 weeks of study entry or a radiopharmaceutical within the past 8 weeks of study entry.
- •Prior malignancy within the past 5 years except for non-melanotic skin cancers.
结局指标
主要结局
Reduce the measurable disease and PSA level by at least 50%
次要结局
- To determine safety and tolerability
研究者
研究点 (2)
Loading locations...
相似试验
招募中
3 期
A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid TumorDesmoid TumorNCT05561036Sun Yat-sen University72
已完成
2 期
Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple MyelomaMultiple MyelomaNCT00201695Ohio State University Comprehensive Cancer Center12
Unknown
2 期
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaMultiple Myeloma and Plasma Cell NeoplasmNCT00742404Oncotherapeutics35
撤回
1 期
A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple MyelomaMultiple MyelomaNCT00516191University of California, San Francisco
已完成
2 期
A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma PatientsMultiple MyelomaNCT00561743Janssen-Ortho Inc., Canada50